Myasthenia Gravis Medication Nipocalimab Outperforms FcRn Blockers in Indirect Comparison Analysis

Indirect treatment comparisons showed significantly greater or statistically higher improvements in MG-ADL scores with nipocalimab versus other FcRn blockers over 24 weeks.:

Source: Neurology Read More

Previous PostGender Disparities in Mood and Quality of Life of Parkinson Disease After DBS: Molly Abbott, BM BCh
Next PostRandomized Trial Highlights Uncertainties of Ambroxol to Improve Cognition in Parkinson Disease Dementia

Myasthenia Gravis Medication Nipocalimab Outperforms FcRn Blockers in Indirect Comparison Analysis

Previous PostGender Disparities in Mood and Quality of Life of Parkinson Disease After DBS: Molly Abbott, BM BCh

Next PostRandomized Trial Highlights Uncertainties of Ambroxol to Improve Cognition in Parkinson Disease Dementia

Related Posts

<![CDATA[Phase 3 Post Hoc Analysis Shows Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in Advanced Parkinson Disease ]]>

<![CDATA[DMD Management: Evolving Regimens and Real-World Adherence]]>

<![CDATA[NeuroVoices: Kate Rosenbluth, PhD, on Expanding Noninvasive Treatment for Essential Tremor With Cala kIQ Plus]]>

Categories